DR3/LARD antibody

Catalog No. ABIN2749178

Product Details anti-DR3/LARD Antibody

Target: DR3/LARD (TNFRSF25) (Tumor Necrosis Factor Receptor Superfamily, Member 25 (TNFRSF25))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This DR3/LARD antibody is un-conjugated

Application: Flow Cytometry (FACS)

Purpose: Anti-DR3 Purified

Specificity: The mouse monoclonal antibody JD3 recognizes an extracellular epitope of DR3 (APO-3, TNFRSF25), a transmembrane protein of TNFR superfamily expressed mainly in lymphocyte-enriched tissues.

Cross-Reactivity (Details): Human

Purification: Purified by protein-A affinity chromatography.

Purity: > 95 % (by SDS-PAGE)

Immunogen: human DR3-Ig fusion protein

Clone: JD3

Isotype: IgG1

Application Details

Application Notes: Flow cytometry: Recommended dilution: 1-4 μg/mL.

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: Store at 2-8°C. Do not freeze.

References for anti-DR3/LARD antibody (ABIN2749178)

Cavallini, Lovato, Bertolaso, Pacelli, Zoratti, Zanolin, Krampera, Zamò, Tecchio, Cassatella, Pizzolo, Scupoli: "The TNF-family cytokine TL1A inhibits proliferation of human activated B cells." in: PLoS ONE, Vol. 8, Issue 4, pp. e60136, (2013) (PubMed).

Yi, Zhang, Schwartz-Albiez, Cao: "Mechanisms of the apoptosis induced by CD176 antibody in human leukemic cells." in: International journal of oncology, Vol. 38, Issue 6, pp. 1565-73, (2011) (PubMed).

Jones, Stumhofer, Foster, Twohig, Hertzog, Topley, Williams, Hunter, Jenkins, Wang, Jones: "Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation." in: FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Vol. 25, Issue 1, pp. 409-19, (2011) (PubMed).

Nakayama, Ishidoh, Kayagaki, Kojima, Yamaguchi, Nakano, Kominami, Okumura, Yagita: "Multiple pathways of TWEAK-induced cell death." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 168, Issue 2, pp. 734-43, (2002) (PubMed).

Target Details for DR3/LARD

Target: DR3/LARD (TNFRSF25) (Tumor Necrosis Factor Receptor Superfamily, Member 25 (TNFRSF25))

Alternative Name: DR3 (TNFRSF25 Products)

Background: TNF receptor superfamily member 25,DR3, also known as APO-3, TRAMP or TNFRSF25, is a death domain-containing receptor of TNFR family, which is expressed preferentially in peripheral blood leukocytes and in the lymphocyte-enriched tissues. Its expression has been shown to be especially up-regulated in activated T cells. DR3 participates e.g. in the removal of self-reactive T cells in the thymus. The ligand for DR3 is TL1A (TNF-like ligand 1A), which is expressed in a variety of cell types (induced by inflammatory stimuli), and can also be released as a soluble factor. The TL1A/DR3 axis has been shown to costimulate T cells to produce a wide variety of cytokines and leads to T cell differentiation towards Th1 and Th17 types.,TNFRSF25, TR3, DDR3, LARD, APO-3, TRAMP, WSL-1, WSL-LR, TNFRSF12

Gene ID: 8718

UniProt: Q93038

Pathways: Apoptosis